ArticleInternational journal of nanomedicine2019
Solid lipid nanoparticles with enteric coating for improving stability, palatability, and oral bioavailability of enrofloxacin.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Integrated analysis of Corylin from Psoralea Corylifolia inhibiting osteoporosis via MAPK pathway.Scientific reports · 2025Article
- Enteric Coating Enhances the Biopharmaceutical Performance of a Silica-Lipid Formulation of Abiraterone Acetate.Pharmaceutics · 2025Article
- Enhancing the Solubility and Oral Bioavailability of Trimethoprim Through PEG-PLGA Nanoparticles: A Comprehensive Evaluation of In Vitro and In Vivo Performance.Pharmaceutics · 2025Article
- Novel Strategies for the Formulation of Poorly Water-Soluble Drug Substances by Different Physical Modification Strategies with a Focus on Peroral Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Preparation andPharmaceutical nanotechnology · 2025Article
- Innovative strategies and nanocarrier approaches for enhancing the oral bioavailability of macromolecular therapeutics.Iranian journal of basic medical sciences · 2025Review
- High Stability and Low Irritation of Enrofloxacin-Colistin Combination Injection Through a Tripartite Strategy.Drug design, development and therapy · 2025Article
- Polymers Enhance Chlortetracycline Hydrochloride Solubility.International journal of molecular sciences · 2024Article
- Intelligent-Responsive Enrofloxacin-Loaded Chitosan Oligosaccharide-Sodium Alginate Composite Core-Shell Nanogels for On-Demand Release in the Intestine.Animals : an open access journal from MDPI · 2022Article
- Antibacterial activity of florfenicol composite nanogels againstJournal of veterinary science · 2022Article
- Mesoporous Silica Carrier-Based Composites for Taste-Masking of Bitter Drug: Fabrication and Palatability Evaluation.AAPS PharmSciTech · 2022Article
- Review
- Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion.Pharmaceutics · 2021Article
- Nanoparticles for treatment of bovineDrug delivery · 2020Review
- Solid Lipid Nanoparticles for Duodenum Targeted Oral Delivery of Tilmicosin.Pharmaceutics · 2020Article
- Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.International journal of nanomedicine · 2020Review
- Enteric-Coated Strategies in Colorectal Cancer Nanoparticle Drug Delivery System.Drug design, development and therapy · 2020Review
- Enhanced Treatment Effects of Tilmicosin AgainstPharmaceutics · 2019Article
- Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe poor palatability, variable oral bioavailability, stimulation to gastric mucosa, and light instability limited the application of enrofloxacin (ENR). The enteric granules combining solid lipid nanoparticles (SLNs) with enteric coating were explored to overcome these disadvantages. MATERIALS AND
methodsENR-loaded SLNs were produced by a hot homogenization and ultrasonic emulsification method and the enteric granules with SLNs as inner core were prepared by wet granulation followed by coating using polyacrylic resin II (PRII). The formulation was optimized by using orthogonal or single factor test screening.
resultsThe optimal SLNs with loading capacity (LC) and price as inspection indexes were consisted of 10 mL 3% polyvinyl alcohol per 0.8 g ENR and 2.4 g octadecanoic acid. The sizes, LC, polydispersion index, and zeta potential of the SLNs were 308.5±6.3 nm, 15.73%±0.31%, 0.352±0.015, and -22.3 mv, respectively. The best enteric granules were used 15% PRII as coating materials. The release of the enteric granules in simulated intestine fluid (SIF, pH=8) was significantly faster than in simulated gastric fluid (SGF, pH=2) and simultaneously slower than those of SLNs and native ENR. The granules showed good stability in influencing factor experiment. The granules displayed a similar daily feed intake as the control group and higher daily feed intake than ENR powder and single-coating granules. Compared to the ENR soluble powder, the area under the plasma concentration-time curve and mean retention time of the enteric granules after intragastric administration were increased from 4.26±0.85 µg h/mL and 6.80±2.28 hours to 11.24±3.33 µg h/mL and 17.97±4.01 hours, respectively.
conclusionThe enteric granules combination SLNs with enteric coating significantly improved the stability, palatability, sustained-release performance and oral bioavailability of ENR. The novel technology will be a potential measure to overcome the similar disadvantages of other drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.